ifinatamab deruxtecan + raludotatug deruxtecan

This is a combination of two antibody-drug conjugates (ADC): - **Ifinatamab deruxtecan** is a humanized anti-B7-H3 IgG1 monoclonal antibody linked to deruxtecan (DXd, a DNA topoisomerase I inhibitor exatecan derivative) via a cleavable tetrapeptide-based linker. It specifically targets B7-H3, overexpressed in many tumor cells, offering a novel antineoplastic mechanism, and is in late-stage clinical development for extensive-stage small cell lung cancer[1][7][9]. - **Raludotatug deruxtecan** is a humanized anti-CDH6 IgG1 monoclonal antibody conjugated to deruxtecan by a similar linker technology, targeting cadherin-6 (CDH6) which is highly expressed in various solid tumors, notably platinum-resistant ovarian, primary peritoneal, and fallopian tube cancers[2][3][4][8][10]. It induces antitumor activity via cellular uptake, lysosomal degradation, and targeted DNA damage in CDH6-expressing tumors. Both drugs have demonstrated efficacy in their respective indications, are engineered using Daiichi Sankyo’s DXd ADC technology, and show potential for combination use in treating solid malignancies.

Other names

anti-B7-H3 ADCanti-B-7-H3 ADCanti-B 7-H3 ADCanti-CDH6 ADC DS-6000aanti-CDH-6 ADC DS-6000aanti-CDH 6 ADC DS-6000aDS-6000DS6000DS 6000MK-5909MK5909MK 5909